PSTX vs. IPSC, KOD, CRDF, GRPH, OPT, IPHA, ABOS, GNFT, ELEV, and CGEN
Should you be buying Poseida Therapeutics stock or one of its competitors? The main competitors of Poseida Therapeutics include Century Therapeutics (IPSC), Kodiak Sciences (KOD), Cardiff Oncology (CRDF), Graphite Bio (GRPH), Opthea (OPT), Innate Pharma (IPHA), Acumen Pharmaceuticals (ABOS), Genfit (GNFT), Elevation Oncology (ELEV), and Compugen (CGEN). These companies are all part of the "biological products, except diagnostic" industry.
Century Therapeutics (NASDAQ:IPSC) and Poseida Therapeutics (NASDAQ:PSTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, community ranking, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.
Poseida Therapeutics has higher revenue and earnings than Century Therapeutics. Poseida Therapeutics is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.
Century Therapeutics currently has a consensus target price of $13.60, suggesting a potential upside of 359.46%. Poseida Therapeutics has a consensus target price of $14.67, suggesting a potential upside of 608.53%. Given Century Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Poseida Therapeutics is more favorable than Century Therapeutics.
50.2% of Century Therapeutics shares are owned by institutional investors. Comparatively, 46.9% of Poseida Therapeutics shares are owned by institutional investors. 7.6% of Century Therapeutics shares are owned by company insiders. Comparatively, 2.1% of Poseida Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Century Therapeutics has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Comparatively, Poseida Therapeutics has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500.
Poseida Therapeutics received 5 more outperform votes than Century Therapeutics when rated by MarketBeat users. Likewise, 64.00% of users gave Poseida Therapeutics an outperform vote while only 60.00% of users gave Century Therapeutics an outperform vote.
Poseida Therapeutics has a net margin of -190.76% compared to Poseida Therapeutics' net margin of -6,115.12%. Poseida Therapeutics' return on equity of -54.73% beat Century Therapeutics' return on equity.
In the previous week, Century Therapeutics had 1 more articles in the media than Poseida Therapeutics. MarketBeat recorded 5 mentions for Century Therapeutics and 4 mentions for Poseida Therapeutics. Poseida Therapeutics' average media sentiment score of 0.59 beat Century Therapeutics' score of 0.07 indicating that Century Therapeutics is being referred to more favorably in the media.
Summary
Century Therapeutics beats Poseida Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Poseida Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PSTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PSTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Poseida Therapeutics Competitors List
Related Companies and Tools
